Net Loss per Share (Tables)

9 Months Ended

Sep. 30, 2024

Earnings Per Share [Abstract]

Schedule of Weighted-Average Common Shares Outstanding

The following securities are the weighted-average common shares outstanding used to calculate basic and diluted net loss per common share:

	Three Months Ended September 30,				Nine Months Ended September 30,
	2024		2023		2024		2023
Common stock		39,360,966		10,287,620		35,824,742		9,206,650
March 2022 pre-funded warrants		-		1,122,819		-		1,227,670
May 2023 Tranche A pre-funded warrants		1,816,427		26,309		2,154,299		8,866
May 2023 Tranche B pre-funded warrants		451,632		-		451,632		-
October 2023 pre-funded warrants		250,000		-		486,496		-
Total		41,879,025		11,436,748		38,917,169		10,443,186

Schedule of Potentially Dilutive Securities Outstanding Excluded from Computations of Diluted Weighted-Average Shares Outstanding

The following potentially dilutive securities outstanding have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented because such securities have an antidilutive impact due to losses reported (in common stock equivalent shares):

	As of September 30,
	2024		2023
Warrants issued to 2010/2012 convertible note    holders to purchase common stock		6,804		6,804
Warrants issued to underwriter to purchase common stock		1,100		1,100
2018 PIPE warrants		-		34,241
March 2022 common warrants		1,273,077		2,130,656
May 2023 Tranche A warrants		-		2,867,908
May 2023 Tranche B warrants		4,935,305		14,000,000
Options to purchase common stock		3,523,251		2,300,412
Outstanding restricted stock units		1,072,530		424,244
Total		10,812,067		21,765,365